This document discusses anxiety disorders and their treatment. It defines anxiety and describes several types of anxiety disorders including generalized anxiety disorder, panic disorder, obsessive-compulsive disorder, post-traumatic stress disorder, and social anxiety disorder. It discusses the causes of anxiety which can include genetics, brain chemistry, life stressors, and certain drugs. Symptoms of anxiety disorders are explained including both physical and emotional effects. The document outlines several treatment approaches for anxiety disorders such as medications, cognitive behavioral therapy, and alternative therapies including exercise, meditation, aromatherapy, and dietary changes.
The document discusses the pharmacology of antidepressant drugs. It begins by defining depression and its various types. It then covers the monoamine hypothesis of depression and classifications of antidepressant drugs. The mechanisms and side effects of various classes are described, including tricyclic antidepressants, SSRIs, SNRIs, MAOIs, and atypical antidepressants. Drug therapy for bipolar disorder involves lithium, anticonvulsants, and antipsychotics. Proper use and monitoring of antidepressant treatment is also outlined.
Schizophrenia is a mental disorder characterized by hallucinations and delusions. The exact cause is unknown but there are several hypotheses including a dopamine imbalance in the brain. Symptoms include changes in behavior, speech abnormalities, hallucinations, and delusions. Treatment involves antipsychotic medications which work by blocking dopamine receptors in the brain. While medications can help control symptoms, schizophrenia has no cure and often becomes a chronic condition.
- Affective disorders include persistent mood disorders like depression that cause socio-occupational dysfunction. Depression is the most common mental disorder.
- The document outlines depression and bipolar affective disorder, their diagnostic criteria, clinical features, management, and when to refer patients. Depression is a leading cause of disability and its early identification and treatment improves outcomes. Bipolar disorder involves episodes of mania or hypomania with or without depression.
This document discusses various types of anxiety disorders including generalized anxiety disorder, social phobia, panic disorder, agoraphobia, specific phobia, post-traumatic stress disorder, and obsessive-compulsive disorder. It covers the definitions, symptoms, epidemiology, pathophysiology, clinical features, investigations, management including psychotherapy and pharmacotherapy, prognosis, and references for each disorder. The management section emphasizes identification of triggers, breathing exercises, thought management, lifestyle changes, cognitive behavioral therapy, and antidepressant or benzodiazepine medication. Prognosis is generally good with proper treatment.
Depression is a state of low mood and loss of interest in activities. It affects thoughts, behavior, motivation, feelings, and well-being. Core symptoms include sadness, difficulty concentrating, changes in appetite and sleep, feelings of dejection and hopelessness, and sometimes suicidal thoughts. Depression can be short or long term. Causes include life events, personality traits, medical treatments, substance use, and psychiatric syndromes. Symptoms include mood disturbances and cognitive changes.
This document discusses antipsychotic medications. It begins by defining psychotic disorders like schizophrenia and their symptoms. It then describes the dopamine, serotonin, and glutamate hypotheses for the causes of schizophrenia. The rest of the document summarizes different classes of antipsychotic medications, including their mechanisms of action, uses, and side effects. It covers both typical/first generation antipsychotics like chlorpromazine as well as atypical/second generation antipsychotics like clozapine, risperidone, and quetiapine.
This document discusses anxiety disorders and their treatment. It defines anxiety and describes several types of anxiety disorders including generalized anxiety disorder, panic disorder, obsessive-compulsive disorder, post-traumatic stress disorder, and social anxiety disorder. It discusses the causes of anxiety which can include genetics, brain chemistry, life stressors, and certain drugs. Symptoms of anxiety disorders are explained including both physical and emotional effects. The document outlines several treatment approaches for anxiety disorders such as medications, cognitive behavioral therapy, and alternative therapies including exercise, meditation, aromatherapy, and dietary changes.
The document discusses the pharmacology of antidepressant drugs. It begins by defining depression and its various types. It then covers the monoamine hypothesis of depression and classifications of antidepressant drugs. The mechanisms and side effects of various classes are described, including tricyclic antidepressants, SSRIs, SNRIs, MAOIs, and atypical antidepressants. Drug therapy for bipolar disorder involves lithium, anticonvulsants, and antipsychotics. Proper use and monitoring of antidepressant treatment is also outlined.
Schizophrenia is a mental disorder characterized by hallucinations and delusions. The exact cause is unknown but there are several hypotheses including a dopamine imbalance in the brain. Symptoms include changes in behavior, speech abnormalities, hallucinations, and delusions. Treatment involves antipsychotic medications which work by blocking dopamine receptors in the brain. While medications can help control symptoms, schizophrenia has no cure and often becomes a chronic condition.
- Affective disorders include persistent mood disorders like depression that cause socio-occupational dysfunction. Depression is the most common mental disorder.
- The document outlines depression and bipolar affective disorder, their diagnostic criteria, clinical features, management, and when to refer patients. Depression is a leading cause of disability and its early identification and treatment improves outcomes. Bipolar disorder involves episodes of mania or hypomania with or without depression.
This document discusses various types of anxiety disorders including generalized anxiety disorder, social phobia, panic disorder, agoraphobia, specific phobia, post-traumatic stress disorder, and obsessive-compulsive disorder. It covers the definitions, symptoms, epidemiology, pathophysiology, clinical features, investigations, management including psychotherapy and pharmacotherapy, prognosis, and references for each disorder. The management section emphasizes identification of triggers, breathing exercises, thought management, lifestyle changes, cognitive behavioral therapy, and antidepressant or benzodiazepine medication. Prognosis is generally good with proper treatment.
Depression is a state of low mood and loss of interest in activities. It affects thoughts, behavior, motivation, feelings, and well-being. Core symptoms include sadness, difficulty concentrating, changes in appetite and sleep, feelings of dejection and hopelessness, and sometimes suicidal thoughts. Depression can be short or long term. Causes include life events, personality traits, medical treatments, substance use, and psychiatric syndromes. Symptoms include mood disturbances and cognitive changes.
This document discusses antipsychotic medications. It begins by defining psychotic disorders like schizophrenia and their symptoms. It then describes the dopamine, serotonin, and glutamate hypotheses for the causes of schizophrenia. The rest of the document summarizes different classes of antipsychotic medications, including their mechanisms of action, uses, and side effects. It covers both typical/first generation antipsychotics like chlorpromazine as well as atypical/second generation antipsychotics like clozapine, risperidone, and quetiapine.
This document provides a summary of typical antipsychotic drugs. It discusses the history of antipsychotics beginning with phenothiazines in the 1950s. It then classifies typical antipsychotics and describes their pharmacokinetics, mechanisms of action, indications, precautions, adverse reactions, and reviews several individual drugs including chlorpromazine, fluphenazine, haloperidol, and zuclopenthixol.
This document discusses various mood disorders including major depressive disorder, dysthymic disorder, bipolar I disorder, and bipolar II disorder. It covers the diagnostic criteria, epidemiology, etiology, course, treatment options, and differential diagnoses for each. Key points include the diagnostic requirements for a major depressive episode, hypomanic episode, and patterns of mood episodes. Treatment involves pharmacotherapy with antidepressants, mood stabilizers, or antipsychotics as well as psychotherapy.
Definition, Epidemiology, Etiology, Aspects of anxiety, Classification/types of anxiety, Pathophysiology of anxiety disorders, Management of anxiety disorders along with treatment algorithms
Depression is a syndrome characterized by low mood and loss of interest. Antidepressants work by increasing levels of neurotransmitters like serotonin and norepinephrine. There are several classes of antidepressants including SSRIs, SNRIs, TCAs, and MAOIs. They have various mechanisms of action and side effects that depend on their pharmacological properties. Other CNS stimulants like caffeine, amphetamines, and modafinil work by increasing neurotransmitters to improve alertness, but can also cause side effects like anxiety, insomnia, and dependence.
This document summarizes the pharmacotherapy of depression. It discusses the major classifications of antidepressants including SSRIs, SNRIs, TCAs, and others. It covers the pathophysiology of depression including the monoamine and neurotrophic hypotheses. For each class of antidepressant, it describes the pharmacokinetics, pharmacodynamics, dosing ranges, adverse effects, and drug interactions. CYP enzyme metabolism is an important factor in antidepressant interactions. The document provides a comprehensive overview of antidepressant treatment of depression and other conditions.
The document discusses the pharmacotherapy of Alzheimer's disease. It defines Alzheimer's as the most common type of dementia and describes its characteristic features and symptoms. The main goals of treatment are symptomatic improvement and disease modification. Current treatments include acetylcholinesterase inhibitors like donepezil which increase acetylcholine levels in the brain, and the NMDA receptor antagonist memantine which blocks glutamate-induced neurotoxicity.
This document discusses various types of anti-depressant medications. It begins by explaining that depression is a medical condition requiring treatment, not a personal fault. It then covers the major classes of anti-depressants including SSRIs, SNRIs, TCAs, MAOIs and others. Each class is described in terms of its mechanism of action, indications, examples of medications, side effects and cautions. Adjunctive treatments like psychotherapy and supplements are also mentioned. The overall summary focuses on the different classes of anti-depressants, their mechanisms and side effect considerations.
The document discusses depression and affective disorders. It defines affective disorders as a set of psychiatric disorders that include depression, bipolar disorder, and related conditions. Depression is described as a mood disorder characterized by loss of interest, feelings of guilt, disturbed sleep or appetite, low energy and poor concentration. The document provides details on the epidemiology, types, etiology, pathophysiology, clinical manifestations, diagnosis, and treatment of depression. Treatment involves lifestyle changes, psychotherapy, antidepressant medication, and in severe cases, electroconvulsive therapy.
Dementia is characterized by deterioration in mental function and impairment in daily activities. Alzheimer's disease is the most common cause and is a progressive neurodegenerative disorder. It involves plaques and tangles of proteins in the brain that damage neurons. Risk factors include age, family history, and medical conditions. Symptoms include memory loss, language problems, and changes in behavior and mood. Diagnosis involves assessing cognitive abilities and daily function, and ruling out other potential causes through tests and scans.
This document summarizes various anti-anxiety drugs including benzodiazepines, 5-HT1A agonists, melatonin receptor agonists, and barbiturates. It describes how these drugs work by potentiating GABA receptors in the brain to produce sedative and anxiolytic effects. Specific drugs mentioned include diazepam, buspirone, remelteon, phenobarbital, and thiopental. The document also discusses the pharmacokinetics, uses, and side effects of these different classes of anti-anxiety medications.
information regarding psychopharmacology especially for nursing students and community. covers all group like anti psychotic, anti anxiety, antidepressants, mood stabilizing agents etc.
Drug Abuse & Misuse, Sedative-Hypnotics “Benzodiazepines”Asra Hameed
Benzodiazepine abuse is a growing problem and carries serious risks to health and society.
Benzodiazepines are commonly used by polydrug abusers, alcoholics and sometimes as primary recreational drugs.
People who abuse benzodiazepines often take very large doses orally, by injection or by snorting.
Benzodiazepine use leads to dependence and a withdrawal syndrome which may include convulsions and psychosis.
Further research is needed on the optimal short-term and long-term management of benzodiazepine abuse.
The primary source of illicit benzodiazepines is from doctors' prescriptions.
This document provides an overview of the pharmacology of antidepressants. It discusses the history of antidepressant development beginning in the 1950s. It then classifies antidepressants and describes the mechanisms of action, pharmacokinetics, pharmacological actions, adverse effects and recent advances for various classes including tricyclic antidepressants, SSRIs, SNRIs, atypical antidepressants. It provides details on specific drugs within each class.
This document provides information on the pharmacology of second generation antipsychotics. It discusses the history and development of antipsychotic drugs from chlorpromazine to clozapine. It describes the mechanisms of action of atypical antipsychotics including their effects on serotonin and dopamine receptors. The document classifies antipsychotics and examines the pharmacology of individual drugs like clozapine, risperidone, and olanzapine, covering their indications, mechanisms, side effects and interactions.
Depression is a mood disorder characterized by persistently low mood and loss of interest for at least two weeks. It affects thoughts, behavior, feelings and well-being. Sadness is temporary while depression is a chronic abnormal emotional state. Types of depression include major depressive disorder, persistent depressive disorder, postpartum depression, psychotic depression, and seasonal affective disorder. Symptoms include depressed mood, loss of interest, changes in appetite or sleep, fatigue, feelings of worthlessness, difficulty concentrating, and suicidal thoughts. The exact causes are unknown but risk factors include genetics, biological factors like neurotransmitter levels, environmental stressors, childhood trauma, and substance abuse. Pathophysiological mechanisms involve the monoamine hypothesis of neurotransmitter
Tricyclic antidepressants (TCAs) share similar chemical structures and biological properties. They are highly lipophilic and tissue-bound outside the central nervous system. Their anticholinergic and noradrenergic effects can cause unpleasant or dangerous side effects. Examples of TCAs described include imipramine, desipramine, clomipramine, amitriptyline, nortriptyline, protriptyline, trimipramine, doxepin, and maprotiline. Selective serotonin reuptake inhibitors have a different structure but some TCAs are metabolized into compounds that are selective norepinephrine reuptake inhibitors. Examples given are flu
This document discusses antipsychotic drugs used to treat schizophrenia and their mechanisms of action and side effects. It focuses on typical antipsychotics which block dopamine D2 receptors in the mesolimbic system. These drugs are used to treat schizophrenia, drug-induced psychoses, and other disorders. Potential adverse effects include sedation, hypotension, anticholinergic effects, extrapyramidal symptoms, weight gain, and tardive dyskinesia. The document also discusses lithium, which is a mood stabilizer used to treat bipolar disorder, and its mechanisms of action and alternatives including sodium valproate, lorazepam, carbamazepine, and lamotrigine.
This document provides an overview of drug therapy for depression. It discusses the following key points:
1. It classifies antidepressants into groups including tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs), and monoamine oxidase inhibitors (MAOIs).
2. It describes the mechanisms of action and effects of these drug classes, with TCAs and SSRIs increasing monoamine neurotransmitter levels by inhibiting reuptake, while MAOIs inhibit the breakdown of monoamines.
3. It notes advantages of SSRIs over TCAs including less cardiotoxicity, fewer anticholinergic side effects, and less risk of interactions,
Anxiety disorders are among the most common mental disorders. They include generalized anxiety disorder, panic disorder, social anxiety disorder, post-traumatic stress disorder, and obsessive-compulsive disorder. Anxiety is caused by an interplay of genetic and environmental factors and involves abnormal activity in brain regions involved in fear and emotion regulation. Treatment involves psychotherapy such as cognitive behavioral therapy and medication like antidepressants and benzodiazepines to reduce symptoms and improve functioning. Untreated anxiety can negatively impact quality of life.
Generalized anxiety disorder is characterized by excessive, uncontrollable worry about everyday life events for at least 6 months. It affects around 3-8% of people, with higher rates in women. Common comorbid disorders include social phobia, panic disorder, and OCD. Both biological and psychosocial factors contribute to its development, such as abnormalities in neurotransmitter systems like GABA and serotonin, and incorrectly perceiving threats. Treatment involves psychotherapy and medication to regulate neurotransmitter activity.
The document provides an overview of foundations of psychiatric mental health nursing. It discusses definitions of mental health and mental illness. It describes the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR) and issues of self-awareness for nurses. Neurobiological theories of mental illness are presented, including the roles of neurotransmitters and neuroanatomic structures. Psychopharmacological treatments for conditions such as schizophrenia, depression, and anxiety are summarized. Finally, psychosocial theories of Sigmund Freud are briefly introduced.
This document provides a summary of typical antipsychotic drugs. It discusses the history of antipsychotics beginning with phenothiazines in the 1950s. It then classifies typical antipsychotics and describes their pharmacokinetics, mechanisms of action, indications, precautions, adverse reactions, and reviews several individual drugs including chlorpromazine, fluphenazine, haloperidol, and zuclopenthixol.
This document discusses various mood disorders including major depressive disorder, dysthymic disorder, bipolar I disorder, and bipolar II disorder. It covers the diagnostic criteria, epidemiology, etiology, course, treatment options, and differential diagnoses for each. Key points include the diagnostic requirements for a major depressive episode, hypomanic episode, and patterns of mood episodes. Treatment involves pharmacotherapy with antidepressants, mood stabilizers, or antipsychotics as well as psychotherapy.
Definition, Epidemiology, Etiology, Aspects of anxiety, Classification/types of anxiety, Pathophysiology of anxiety disorders, Management of anxiety disorders along with treatment algorithms
Depression is a syndrome characterized by low mood and loss of interest. Antidepressants work by increasing levels of neurotransmitters like serotonin and norepinephrine. There are several classes of antidepressants including SSRIs, SNRIs, TCAs, and MAOIs. They have various mechanisms of action and side effects that depend on their pharmacological properties. Other CNS stimulants like caffeine, amphetamines, and modafinil work by increasing neurotransmitters to improve alertness, but can also cause side effects like anxiety, insomnia, and dependence.
This document summarizes the pharmacotherapy of depression. It discusses the major classifications of antidepressants including SSRIs, SNRIs, TCAs, and others. It covers the pathophysiology of depression including the monoamine and neurotrophic hypotheses. For each class of antidepressant, it describes the pharmacokinetics, pharmacodynamics, dosing ranges, adverse effects, and drug interactions. CYP enzyme metabolism is an important factor in antidepressant interactions. The document provides a comprehensive overview of antidepressant treatment of depression and other conditions.
The document discusses the pharmacotherapy of Alzheimer's disease. It defines Alzheimer's as the most common type of dementia and describes its characteristic features and symptoms. The main goals of treatment are symptomatic improvement and disease modification. Current treatments include acetylcholinesterase inhibitors like donepezil which increase acetylcholine levels in the brain, and the NMDA receptor antagonist memantine which blocks glutamate-induced neurotoxicity.
This document discusses various types of anti-depressant medications. It begins by explaining that depression is a medical condition requiring treatment, not a personal fault. It then covers the major classes of anti-depressants including SSRIs, SNRIs, TCAs, MAOIs and others. Each class is described in terms of its mechanism of action, indications, examples of medications, side effects and cautions. Adjunctive treatments like psychotherapy and supplements are also mentioned. The overall summary focuses on the different classes of anti-depressants, their mechanisms and side effect considerations.
The document discusses depression and affective disorders. It defines affective disorders as a set of psychiatric disorders that include depression, bipolar disorder, and related conditions. Depression is described as a mood disorder characterized by loss of interest, feelings of guilt, disturbed sleep or appetite, low energy and poor concentration. The document provides details on the epidemiology, types, etiology, pathophysiology, clinical manifestations, diagnosis, and treatment of depression. Treatment involves lifestyle changes, psychotherapy, antidepressant medication, and in severe cases, electroconvulsive therapy.
Dementia is characterized by deterioration in mental function and impairment in daily activities. Alzheimer's disease is the most common cause and is a progressive neurodegenerative disorder. It involves plaques and tangles of proteins in the brain that damage neurons. Risk factors include age, family history, and medical conditions. Symptoms include memory loss, language problems, and changes in behavior and mood. Diagnosis involves assessing cognitive abilities and daily function, and ruling out other potential causes through tests and scans.
This document summarizes various anti-anxiety drugs including benzodiazepines, 5-HT1A agonists, melatonin receptor agonists, and barbiturates. It describes how these drugs work by potentiating GABA receptors in the brain to produce sedative and anxiolytic effects. Specific drugs mentioned include diazepam, buspirone, remelteon, phenobarbital, and thiopental. The document also discusses the pharmacokinetics, uses, and side effects of these different classes of anti-anxiety medications.
information regarding psychopharmacology especially for nursing students and community. covers all group like anti psychotic, anti anxiety, antidepressants, mood stabilizing agents etc.
Drug Abuse & Misuse, Sedative-Hypnotics “Benzodiazepines”Asra Hameed
Benzodiazepine abuse is a growing problem and carries serious risks to health and society.
Benzodiazepines are commonly used by polydrug abusers, alcoholics and sometimes as primary recreational drugs.
People who abuse benzodiazepines often take very large doses orally, by injection or by snorting.
Benzodiazepine use leads to dependence and a withdrawal syndrome which may include convulsions and psychosis.
Further research is needed on the optimal short-term and long-term management of benzodiazepine abuse.
The primary source of illicit benzodiazepines is from doctors' prescriptions.
This document provides an overview of the pharmacology of antidepressants. It discusses the history of antidepressant development beginning in the 1950s. It then classifies antidepressants and describes the mechanisms of action, pharmacokinetics, pharmacological actions, adverse effects and recent advances for various classes including tricyclic antidepressants, SSRIs, SNRIs, atypical antidepressants. It provides details on specific drugs within each class.
This document provides information on the pharmacology of second generation antipsychotics. It discusses the history and development of antipsychotic drugs from chlorpromazine to clozapine. It describes the mechanisms of action of atypical antipsychotics including their effects on serotonin and dopamine receptors. The document classifies antipsychotics and examines the pharmacology of individual drugs like clozapine, risperidone, and olanzapine, covering their indications, mechanisms, side effects and interactions.
Depression is a mood disorder characterized by persistently low mood and loss of interest for at least two weeks. It affects thoughts, behavior, feelings and well-being. Sadness is temporary while depression is a chronic abnormal emotional state. Types of depression include major depressive disorder, persistent depressive disorder, postpartum depression, psychotic depression, and seasonal affective disorder. Symptoms include depressed mood, loss of interest, changes in appetite or sleep, fatigue, feelings of worthlessness, difficulty concentrating, and suicidal thoughts. The exact causes are unknown but risk factors include genetics, biological factors like neurotransmitter levels, environmental stressors, childhood trauma, and substance abuse. Pathophysiological mechanisms involve the monoamine hypothesis of neurotransmitter
Tricyclic antidepressants (TCAs) share similar chemical structures and biological properties. They are highly lipophilic and tissue-bound outside the central nervous system. Their anticholinergic and noradrenergic effects can cause unpleasant or dangerous side effects. Examples of TCAs described include imipramine, desipramine, clomipramine, amitriptyline, nortriptyline, protriptyline, trimipramine, doxepin, and maprotiline. Selective serotonin reuptake inhibitors have a different structure but some TCAs are metabolized into compounds that are selective norepinephrine reuptake inhibitors. Examples given are flu
This document discusses antipsychotic drugs used to treat schizophrenia and their mechanisms of action and side effects. It focuses on typical antipsychotics which block dopamine D2 receptors in the mesolimbic system. These drugs are used to treat schizophrenia, drug-induced psychoses, and other disorders. Potential adverse effects include sedation, hypotension, anticholinergic effects, extrapyramidal symptoms, weight gain, and tardive dyskinesia. The document also discusses lithium, which is a mood stabilizer used to treat bipolar disorder, and its mechanisms of action and alternatives including sodium valproate, lorazepam, carbamazepine, and lamotrigine.
This document provides an overview of drug therapy for depression. It discusses the following key points:
1. It classifies antidepressants into groups including tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs), and monoamine oxidase inhibitors (MAOIs).
2. It describes the mechanisms of action and effects of these drug classes, with TCAs and SSRIs increasing monoamine neurotransmitter levels by inhibiting reuptake, while MAOIs inhibit the breakdown of monoamines.
3. It notes advantages of SSRIs over TCAs including less cardiotoxicity, fewer anticholinergic side effects, and less risk of interactions,
Anxiety disorders are among the most common mental disorders. They include generalized anxiety disorder, panic disorder, social anxiety disorder, post-traumatic stress disorder, and obsessive-compulsive disorder. Anxiety is caused by an interplay of genetic and environmental factors and involves abnormal activity in brain regions involved in fear and emotion regulation. Treatment involves psychotherapy such as cognitive behavioral therapy and medication like antidepressants and benzodiazepines to reduce symptoms and improve functioning. Untreated anxiety can negatively impact quality of life.
Generalized anxiety disorder is characterized by excessive, uncontrollable worry about everyday life events for at least 6 months. It affects around 3-8% of people, with higher rates in women. Common comorbid disorders include social phobia, panic disorder, and OCD. Both biological and psychosocial factors contribute to its development, such as abnormalities in neurotransmitter systems like GABA and serotonin, and incorrectly perceiving threats. Treatment involves psychotherapy and medication to regulate neurotransmitter activity.
The document provides an overview of foundations of psychiatric mental health nursing. It discusses definitions of mental health and mental illness. It describes the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR) and issues of self-awareness for nurses. Neurobiological theories of mental illness are presented, including the roles of neurotransmitters and neuroanatomic structures. Psychopharmacological treatments for conditions such as schizophrenia, depression, and anxiety are summarized. Finally, psychosocial theories of Sigmund Freud are briefly introduced.
This document provides information on anxiety disorders, including definitions, classifications, epidemiology, symptoms, pathophysiology, treatment options and specific details on generalized anxiety disorder, panic disorder, phobic disorders, post-traumatic stress disorder, and obsessive-compulsive disorder. It discusses the role of the GABA, serotonin and norepinephrine systems in the pathophysiology of anxiety disorders. It also summarizes pharmacological treatments including SSRIs, TCAs, MAOIs, benzodiazepines, and buspirone as well as cognitive behavioral therapy.
This document provides information on anxiety disorders, including definitions, classifications, epidemiology, symptoms, pathophysiology, and treatment options. It discusses several specific anxiety disorders - generalized anxiety disorder, panic disorder, phobic disorders, post-traumatic stress disorder, and obsessive-compulsive disorder. For each, it outlines diagnostic criteria, clinical presentation, risk factors, and mechanisms. The document also reviews pharmacological treatments for anxiety including SSRIs, TCAs, MAOIs, benzodiazepines, and buspirone. Non-pharmacological options like CBT are also mentioned.
This document discusses anxiety disorders. It defines anxiety and pathological anxiety, and notes that anxiety disorders are associated with neurotransmitter imbalances involving serotonin, noradrenaline, and GABA. It then describes several types of anxiety disorders including panic disorder, separation anxiety disorder, specific phobia, social anxiety disorder, and generalized anxiety disorder. The document outlines biological and medical causes of anxiety disorders and lists common symptoms. It concludes with a discussion of assessment, management through pharmacotherapy and psychotherapy, and medications used to treat different anxiety disorders.
This document provides an overview of anxiety disorders. It begins with an introduction section and then discusses symptoms, epidemiology, and classifications of anxiety disorders. Specific types of anxiety disorders covered include generalized anxiety disorder, phobic anxiety disorders (including specific phobia, social phobia, and agoraphobia), panic disorder, and post-traumatic stress disorder. Contributions of psychological and biological sciences to understanding anxiety disorders are also reviewed. The document concludes with a discussion of diagnostic criteria and classifications of anxiety disorders according to diagnostic manuals.
Hello friends. In this PPT I am talking about CNS drugs. If you like it, please do let me know in the comments section. A single word of appreciation from you will encourage me to make more of such videos. Thanks. Enjoy and welcome to the beautiful world of pharmacology where pharmacology comes to life. This video is intended for MBBS, BDS, paramedical and any person who wishes to have a basic understanding of the subject in the simplest way.
1. Schizophrenia is a chronic and severe mental disorder characterized by distortions in thinking, perception, emotions, language, sense of self and behavior.
2. It affects about 1% of the population and is one of the most challenging diseases for psychiatrists to treat.
3. The causes are unknown but likely involve a combination of genetic, biological, environmental, and psychological factors. Management involves antipsychotic medications along with psychosocial therapies.
A presentation about panic attacks and panic disorder. this presentation composed of the definition, causes, symptoms, diagnosis, treatment, prevention and prognosis of panic disorder.
This document discusses different types of reactions to stressful situations:
1. Acute stress reaction - a transient disorder developing in response to exceptional stress that usually subsides within hours or days. Symptoms include withdrawal, anger, and grief.
2. Post-traumatic stress disorder (PTSD) - a delayed response to a traumatic event causing intrusive memories, avoidance, and hyperarousal for over a month.
3. Adjustment disorder - distress interfering with functioning in response to a significant life change, with symptoms like depressed mood and anxiety lasting less than 6 months.
Anxiety disorders are among the most common psychiatric disorders and cause significant distress and impairment. They involve unrealistic and excessive fears or anxiety. There are several types of anxiety disorders including generalized anxiety disorder, panic disorder, phobias, obsessive compulsive disorder, post-traumatic stress disorder, and acute stress disorder. Effective treatments involve psychotherapy, pharmacotherapy, and supportive therapy with goals of reducing anxiety symptoms and improving coping and functioning. Nursing care focuses on safety, education, teaching coping skills, and supporting treatment plans.
This document provides an overview of abnormal psychology. It begins by defining mental health and abnormal psychology. It then discusses approaches for distinguishing normal from abnormal behavior, including deviation from social norms and the 4 Ds model focusing on distress, danger, dysfunction, and disability. The document outlines major classifications of mental disorders in the DSM-5 including neurotic disorders like anxiety and depression, and psychotic disorders like schizophrenia. Several specific psychological disorders are then defined, including panic disorder, major depressive disorder, schizophrenia, PTSD, OCD, and bipolar disorder. Finally, the document discusses treatments for psychological disorders which include psychological, biomedical, and social approaches.
Antidepressants are the second most prescribed medication in the US, with 15 million Americans affected by depression each year. Depression is treated through medications and therapy. Antidepressants work by adjusting neurotransmitter levels in the brain like serotonin, dopamine, and norepinephrine. Common classes include SSRIs, SNRIs, TCAs, and MAOIs. While effective, antidepressants can cause side effects like nausea, insomnia, sexual dysfunction, and increased suicide risk initially. Doctors closely monitor patients to improve treatment outcomes and safety.
This document provides an overview of understanding psychological injuries in the workplace. It defines psychological injury as a diagnosable mental illness that can disrupt ability to work. Common causes of workplace psychological injuries include heavy workloads, shift work, and poor management styles. Psychological injuries are diagnosed using systems like DSM-5 and ICD-10 and common conditions include adjustment disorder, depression, anxiety, and PTSD. Substance use can also impact mental health. Managing psychological injuries requires collaboration between the worker, employer, treating practitioner, and case manager to support treatment and return to work.
Disorder for mood and very useful for psychiatryIshanJain1034
Psychosis involves a loss of contact with reality and can include delusions and hallucinations. It is distinguished from neurosis which involves chronic distress but not distortions in reality. Brief psychotic disorder involves psychotic symptoms for less than 1 month. Delusional disorder involves non-bizarre delusions for over 1 month. Schizoaffective disorder involves psychotic and mood symptoms. Psychosis can also be due to medical conditions or substance use.
This document discusses various concepts related to psychopathology and mental disorders. It defines a mental disorder as a clinically significant disturbance in cognition, conation, or affect that causes distress or disability. It outlines the World Health Organization's classification of mental disorders into 10 classes. Specific anxiety disorders like generalized anxiety disorder, panic disorder, and obsessive-compulsive disorder are explained in terms of their clinical features. The pathophysiology and management of anxiety disorders through pharmacotherapy and psychosocial treatments are also summarized.
Schizophrenia is a psychiatric syndrome characterized by disintegration of personality and disturbances in thinking, emotion, behavior, and volition. It is classified into several subtypes including simple, hebephrenic, catatonic, paranoid, and residual schizophrenia. Diagnosis involves symptoms like thought withdrawal, insertion, broadcasting, and hallucinatory voices. Treatment involves hospitalization, antipsychotic medications tailored to the subtype, and psychosocial therapies like cognitive behavioral therapy.
This document provides an overview of case-control surveillance studies. It discusses that case-control studies are retrospective and aim to determine if an exposure is associated with an outcome. The document outlines how cases and controls are selected and defined, and how odds ratios are used to interpret the association between an exposure and disease. It also discusses potential sources of bias and confounding, and notes some key advantages and disadvantages of the case-control study design.
Liver Function Tests (LFTs) provide information about liver health and disease processes. They include tests of liver transport and metabolism (bilirubin, albumin), hepatocyte injury (aminotransferases, alkaline phosphatase), and biosynthetic function (proteins, ceruloplasmin). Bilirubin and albumin directly assess liver function, while enzymes indicate hepatocyte damage. Elevated enzymes suggest hepatitis. Bilirubin levels distinguish hepatocellular from cholestatic processes. Albumin declines with cirrhosis. LFTs help pharmacists monitor for drug-induced liver injury.
Nutrition of patients undergoing dialysisManiz Joshi
This document discusses nutritional assessment and dietary recommendations for dialysis patients. It outlines several methods for assessing nutritional status, including physical exams, body composition measurements, functional tests, and biochemical markers like serum albumin and prealbumin. Optimal intake levels are provided for proteins, sodium, fluids, potassium, phosphorus, and various vitamins. Maintaining adequate nutrition through diet and supplements is important for dialysis patients given losses during treatment and high risk of malnutrition.
Role and responsibilities of investigators as per ichManiz Joshi
An investigator must be a qualified physician responsible for medical decisions, have suitable education and experience, and knowledge of good clinical practice. They may delegate some responsibilities to trained individuals. The investigator should permit monitoring and auditing.
The investigator must demonstrate the ability to recruit enough subjects in the agreed time period. They must have sufficient time and qualified staff to properly conduct the trial according to the protocol.
The investigator is responsible for medical care and decisions for subjects, and must ensure medical care is provided for any adverse events. They should communicate with subjects' primary physicians if agreed to. The investigator must obtain approval from an ethics committee and comply with the approved protocol.
Pneumonia is an inflammatory lung condition caused by bacteria or viruses that enter the lungs. When pathogens enter the alveoli, or air sacs, white blood cells rush to fight the infection, filling the sacs with fluid and pus. Streptococcus pneumoniae is the most common bacterial cause. Risk factors include old age, smoking, lung diseases, and weakened immunity. Symptoms include fever, chills, cough with colored mucus, chest pain, and difficulty breathing. Diagnosis involves physical exam, chest x-rays, and tests of sputum or blood. Antibiotics treat bacterial pneumonia while rest and fluids help viral cases. Vaccines can prevent pneumococcal pneumonia.
Adverse drug reactions of tetracycline antibioticsManiz Joshi
Tetracycline antibiotics can cause adverse drug reactions including irritative effects like epigastric pain, nausea, vomiting and diarrhea. They may also cause liver damage through fatty infiltration and jaundice, and kidney damage, especially in the presence of existing kidney disease. Tetracycline antibiotics are also phototoxic and can cause sunburn-like skin reactions. When taken during pregnancy, childhood or tooth development, they may cause permanent tooth staining or suppression of bone growth by depositing calcium-tetracycline chelates in developing teeth and bones. Other adverse reactions include anti-anabolic effects, increased intracranial pressure in infants, diabetes insipidus, and vestibular toxicity with minocycline.
This ppt goes out to all the pharmacy students and lecturers. Check my other ppt slides too and do not forget to like and share! :) Thank you for the visit :D
Refrigeration and air conditioning systems use a refrigeration cycle to remove heat from an enclosed space and lower its temperature. The refrigeration cycle involves compressing a refrigerant vapor, condensing it into a liquid, expanding the liquid to produce cooling, and evaporating the liquid to remove heat. Common applications of refrigeration include cooling food in refrigerators and preserving temperature-sensitive substances like vaccines or hormones. Proper heating, ventilation, and air conditioning systems are also important for manufacturing pharmaceuticals by maintaining environmental conditions, preventing contamination, and protecting personnel comfort and health.
These lecture slides, by Dr Sidra Arshad, offer a simplified look into the mechanisms involved in the regulation of respiration:
Learning objectives:
1. Describe the organisation of respiratory center
2. Describe the nervous control of inspiration and respiratory rhythm
3. Describe the functions of the dorsal and respiratory groups of neurons
4. Describe the influences of the Pneumotaxic and Apneustic centers
5. Explain the role of Hering-Breur inflation reflex in regulation of inspiration
6. Explain the role of central chemoreceptors in regulation of respiration
7. Explain the role of peripheral chemoreceptors in regulation of respiration
8. Explain the regulation of respiration during exercise
9. Integrate the respiratory regulatory mechanisms
10. Describe the Cheyne-Stokes breathing
Study Resources:
1. Chapter 42, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 36, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 13, Human Physiology by Lauralee Sherwood, 9th edition
Rasamanikya is a excellent preparation in the field of Rasashastra, it is used in various Kushtha Roga, Shwasa, Vicharchika, Bhagandara, Vatarakta, and Phiranga Roga. In this article Preparation& Comparative analytical profile for both Formulationon i.e Rasamanikya prepared by Kushmanda swarasa & Churnodhaka Shodita Haratala. The study aims to provide insights into the comparative efficacy and analytical aspects of these formulations for enhanced therapeutic outcomes.
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central19various
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
Histololgy of Female Reproductive System.pptxAyeshaZaid1
Dive into an in-depth exploration of the histological structure of female reproductive system with this comprehensive lecture. Presented by Dr. Ayesha Irfan, Assistant Professor of Anatomy, this presentation covers the Gross anatomy and functional histology of the female reproductive organs. Ideal for students, educators, and anyone interested in medical science, this lecture provides clear explanations, detailed diagrams, and valuable insights into female reproductive system. Enhance your knowledge and understanding of this essential aspect of human biology.
- Video recording of this lecture in English language: https://youtu.be/kqbnxVAZs-0
- Video recording of this lecture in Arabic language: https://youtu.be/SINlygW1Mpc
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Does Over-Masturbation Contribute to Chronic Prostatitis.pptxwalterHu5
In some case, your chronic prostatitis may be related to over-masturbation. Generally, natural medicine Diuretic and Anti-inflammatory Pill can help mee get a cure.
TEST BANK For Community Health Nursing A Canadian Perspective, 5th Edition by...Donc Test
TEST BANK For Community Health Nursing A Canadian Perspective, 5th Edition by Stamler, Verified Chapters 1 - 33, Complete Newest Version Community Health Nursing A Canadian Perspective, 5th Edition by Stamler, Verified Chapters 1 - 33, Complete Newest Version Community Health Nursing A Canadian Perspective, 5th Edition by Stamler Community Health Nursing A Canadian Perspective, 5th Edition TEST BANK by Stamler Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Pdf Chapters Download Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Pdf Download Stuvia Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Study Guide Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Ebook Download Stuvia Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Questions and Answers Quizlet Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Studocu Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Quizlet Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Stuvia Community Health Nursing A Canadian Perspective, 5th Edition Pdf Chapters Download Community Health Nursing A Canadian Perspective, 5th Edition Pdf Download Course Hero Community Health Nursing A Canadian Perspective, 5th Edition Answers Quizlet Community Health Nursing A Canadian Perspective, 5th Edition Ebook Download Course hero Community Health Nursing A Canadian Perspective, 5th Edition Questions and Answers Community Health Nursing A Canadian Perspective, 5th Edition Studocu Community Health Nursing A Canadian Perspective, 5th Edition Quizlet Community Health Nursing A Canadian Perspective, 5th Edition Stuvia Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Pdf Chapters Download Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Pdf Download Stuvia Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Study Guide Questions and Answers Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Ebook Download Stuvia Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Questions Quizlet Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Studocu Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Quizlet Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Stuvia
TEST BANK For Community and Public Health Nursing: Evidence for Practice, 3rd...Donc Test
TEST BANK For Community and Public Health Nursing: Evidence for Practice, 3rd Edition by DeMarco, Walsh, Verified Chapters 1 - 25, Complete Newest Version TEST BANK For Community and Public Health Nursing: Evidence for Practice, 3rd Edition by DeMarco, Walsh, Verified Chapters 1 - 25, Complete Newest Version TEST BANK For Community and Public Health Nursing: Evidence for Practice, 3rd Edition by DeMarco, Walsh, Verified Chapters 1 - 25, Complete Newest Version Test Bank For Community and Public Health Nursing: Evidence for Practice 3rd Edition Pdf Chapters Download Test Bank For Community and Public Health Nursing: Evidence for Practice 3rd Edition Pdf Download Stuvia Test Bank For Community and Public Health Nursing: Evidence for Practice 3rd Edition Study Guide Test Bank For Community and Public Health Nursing: Evidence for Practice 3rd Edition Ebook Download Stuvia Test Bank For Community and Public Health Nursing: Evidence for Practice 3rd Edition Questions and Answers Quizlet Test Bank For Community and Public Health Nursing: Evidence for Practice 3rd Edition Studocu Test Bank For Community and Public Health Nursing: Evidence for Practice 3rd Edition Quizlet Test Bank For Community and Public Health Nursing: Evidence for Practice 3rd Edition Stuvia Community and Public Health Nursing: Evidence for Practice 3rd Edition Pdf Chapters Download Community and Public Health Nursing: Evidence for Practice 3rd Edition Pdf Download Course Hero Community and Public Health Nursing: Evidence for Practice 3rd Edition Answers Quizlet Community and Public Health Nursing: Evidence for Practice 3rd Edition Ebook Download Course hero Community and Public Health Nursing: Evidence for Practice 3rd Edition Questions and Answers Community and Public Health Nursing: Evidence for Practice 3rd Edition Studocu Community and Public Health Nursing: Evidence for Practice 3rd Edition Quizlet Community and Public Health Nursing: Evidence for Practice 3rd Edition Stuvia Community and Public Health Nursing: Evidence for Practice 3rd Edition Test Bank Pdf Chapters Download Community and Public Health Nursing: Evidence for Practice 3rd Edition Test Bank Pdf Download Stuvia Community and Public Health Nursing: Evidence for Practice 3rd Edition Test Bank Study Guide Questions and Answers Community and Public Health Nursing: Evidence for Practice 3rd Edition Test Bank Ebook Download Stuvia Community and Public Health Nursing: Evidence for Practice 3rd Edition Test Bank Questions Quizlet Community and Public Health Nursing: Evidence for Practice 3rd Edition Test Bank Studocu Community and Public Health Nursing: Evidence for Practice 3rd Edition Test Bank Quizlet Community and Public Health Nursing: Evidence for Practice 3rd Edition Test Bank Stuvia
Osteoporosis - Definition , Evaluation and Management .pdfJim Jacob Roy
Osteoporosis is an increasing cause of morbidity among the elderly.
In this document , a brief outline of osteoporosis is given , including the risk factors of osteoporosis fractures , the indications for testing bone mineral density and the management of osteoporosis
1. Anxiety Disorder
Presented by: Usha Pokharel and Manij Joshi
Masters in Pharmaceutical Care
Kathmandu University, Dhulikhel, Kavre, Nepal.
2. Anxiety Disorder
• As defined by American Psychological Association; Anxiety is an
emotion characterized by feelings of tension, worried thoughts and
physical changes like increased blood pressure.
3. Pathophysiology
• The pathophysiologic mechanisms of anxiety disorders
have yet to be fully elucidated.
• Several neurotransmitters mediate anxiety. These include
inhibitory amino acids such as:
1. γ- amino butyric acid (GABA)
2. Noradrenergic model
3. 5HT model
4. γ-Aminobutyric acid (GABA) receptor model:
• GABA is the major inhibitory neurotransmitter in the
central nervous system (CNS).
• Considerable evidence links GABAA receptor dysfunction
and the pathophysiology of anxiety disorders.GABAA
receptors act as gatekeepers for chloride channels and
have multiple modulatory sites such as benzodiazepine
(BZD) receptors.
• In normal individuals GABAA binds to the GABA
receptors and opens up the chloride ion channels
causing hyper polarization and thus decreasing cellular
excitability.
• Anxiety symptoms may be linked to under activity of
GABA system.
5.
6. • In generalized SAD(Social Anxiety Disorder) may occur
due to abnormal central GABA(B) receptor function .
• Abnormalities of GABA(A) inhibition leads to increased
( ) response to stress in Post Traumatic Stress
Disorder(PTSD).
7. Noradrenergic model
• This model suggests that the autonomic nervous system of
anxious patients is hypersensitive and overreacts to various
stimuli.
• The locus ceruleus may have a role in regulating anxiety, as
it activates nor epinephrine release and stimulates the
sympathetic and parasympathetic nervous systems.
• Chronic noradrenergic over activity down regulates α2-
adrenoreceptors in patients with generalized anxiety
disorder (GAD) and posttraumatic stress disorder (PTSD).
• Patients with social anxiety disorder (SAD) appear to have a
hyper responsive adrenocortical response to psychological
stress.
8.
9.
10. 5HT MODEL
• The major serotonergic systems
originate in the raphe nuclei(in
brain stem) and project to the
areas throughout the brain.
• These projections appear to have
primarily inhibitory function
acting in opposition to
cholinergic, noradrenergic and
dopaminergic projections.
• Increased serotonergic activity is
associated with reduced levels of
behavioral activation and arousal,
serotonin plays an important role
in sleep, mood , appetite,
temperature regulation and pain
perception.
Moderate sized cluster
found in brain stem , they
have 5HT1 receptors in brain
which functions as
autoreceptors in brain.
11. TYPES OF ANXIETY DISORDERS
1. GENERALIZED ANXIETY DISORDER
2. PANIC DISORDER
3. Social Anxiety Disorder
4. Post Traumatic Stress Disorder
12. GENERALIZED ANXIETY DISORDER
The diagnosis of GAD requires excessive anxiety and worry
most days about a number of matters for at least 6
months. Symptoms are at least three of the following:
PHYSICAL PSYCHOLOGICAL
RESTLESSNESS EXCESSIVE ANXIETY
FATIGUE WORRIES that are difficult to
control
MUSCLE WEAKNESS Feeling keyed up
SLEEP DISTURBANCES Poor concentration or mind
going blank
IRRITABILITY
13. • Persons with GAD may have endured their symptoms for
many years, without recognizing that such symptoms are
out of the ordinary.
• The pattern of onset of GAD differs from that of other
anxiety disorders. Most anxiety disorders have their onset
before the age of 20 years, rates of GAD in the young are
usually low, with substantially increasing prevalence
observed with advancing age.
• Women are approximately twice as likely as men to have
GAD.
14. PANIC DISORDER
In panic disorder, the attacks are triggered randomly and are
followed by:
• At least 1 month of persistent concern about the possibility of
additional panic attacks.
• Worry about the consequences of the attacks
• Significant behavioral changes related to the attacks.
The frequency and severity of panic attacks vary widely, with
some persons having
• Moderately frequent attacks (e.g., once weekly for months at
a time)
• Others reporting short bursts of attacks (e.g., daily for a
week)
• and still others reporting infrequent attacks (e.g., two per
month over many years
15. CLINICAL PRESENTATION OF PANIC ATTACKS
Depersonalization: It is
described as a feeling
disconnected or detached
from one’s self
16. Derealization: It is a feeling that
one’s surroundings are not real,
especially as a symptom of mental
disturbance.
18. • During an attack, there must be at least four physical
symptoms in addition to intense fear or discomfort.
• Symptoms reach a peak within 10 minutes and usually
last no more than 20 or 30 minutes.
• Up to 70% of patients eventually develop agoraphobia,
which is avoidance of specific situations (e g, being in
crowded places or crossing bridges) where they fear a
panic attack might occur. Patients may become
homebound
19. SOCIAL ANXIETY DISORDER
• SAD is a chronic disorder with an intense fear or anxiety
about one or more social situations in which there is
scrutiny by others which may result in negative
evaluation and rejection.
• Exposure to the feared situation(s) almost always
provokes fear or anxiety, and the situations are avoided
or endured with intense anxiety.
20. Fears Of Being
• Scrutinized by others
• Embarrassed
• Humiliated
Some Feared Situations
• Eating or writing in front of others
• Interacting with authority figures
• Speaking in public
• Talking with strangers
22. POST TRAUMATIC STRESS DISORDER
• PTSD is characterized by the development of symptoms after
a person experiences or witnesses a traumatic event in which
actual or threatened death or serious injury occurs.
• Core symptoms of PTSD are grouped into three domains:
1. Experiencing the traumatic event (e.g., nightmares or
flashbacks)
2. Avoidance of associated stimuli or an emotional numbing
of general responsiveness
3. Hyper arousal (e.g., sleep difficulties, hyper vigilance,
exaggerated startle response, irritability or anger
outbursts).
For the diagnosis of PTSD to be made, symptoms must be
present for at least 1 month and must cause significant
functional impairment.
23. • For example: A traumatic event was experienced in which
the individual witnessed, experienced, or was confronted
with actual or threatened death or serious injury and to
which the person responded with intense fear, helplessness,
or horror.
• Traumatic event is re-experienced persistently in some way
(e.g., nightmares, flashbacks), or intense distress is
experienced on exposure to stimuli associated with the
traumatic event.
24. The individual persistently avoids stimuli associated with the
event and numbing of general responsiveness occurs,
involving at least three of the following:
1. Efforts to avoid thoughts, feelings, or conversations
associated with the trauma.
2. Efforts to avoid activities, places, or people that are
reminders of the trauma.
3. Inability to recall an important aspect of the trauma
4. Markedly diminished interest in significant activities.
5. Feeling of detachment or estrangement from others
6. Restricted range of affect
7. Sense of foreshortened future
25. Persistent symptoms of increased arousal occur, involving at
least two of the following:
1. Difficulty falling or staying asleep
2. Irritability or angry outbursts
3. Difficulty concentrating
4. Hyper vigilance( a person experiencing it will have an
enhanced state of sensory sensitivity accompanied by
exaggerated behavior).
5. Exaggerated startle response
Above symptoms endure for at least 1 month
Symptoms cause clinically significant impairment in social,
occupational, or other important area of functioning.
26. Treatment
• Treatment for anxiety disorders often requires multiple approaches.
The patient may need short-term treatment with an anxiolytic, such
as a benzodiazepine, to help reduce the immediate symptoms
combined with psychological therapies and an antidepressant for
longer term treatment and prevention of symptoms returning.
27. 1. Psychotherapy
• Psychological therapies (talking therapies) are generally considered first-
line treatments in all anxiety disorders because they may provide a longer
lasting response and lower relapse rates than pharmacotherapy.
Psychotherapy, however, is less available, more demanding and takes
longer time to work than pharmacotherapy. If the patient is unable to
tolerate the anxiety or associated distress, then medicines are often used
before psychotherapy or while awaiting psychotherapy.
• The specific psychotherapy with the most supporting evidence in anxiety
disorders is cognitive behavioural therapy (CBT). Cognitive behaviour
therapy focuses on the ‘here and now’ and explores how the individual
feels about themselves and others and how behaviour is related to these
thoughts.
28. 2. Pharmacotherapy
A. Benzodiazepines
• Benzodiazepines are commonly prescribed to provide
immediate relief of the symptoms of severe anxiety.
These drugs differ considerably in potency (equivalent
dosage) and in rate of elimination but only slightly in
clinical effects.
Mechanism of Action
• The effects of benzodiazepines result from their
interaction with specific binding sites associated with
postsynaptic GABA (A) receptors in the brain and
potentiation of influx of chlorine ion.
• GABA is the most important inhibitory neurotransmitter
in the central nervous system (CNS). Neuronal activity in
the CNS is regulated by the balance between GABA
inhibitory activity and excitatory neurotransmitters such
as glutamate. If the balance swings towards more GABA
activity, sedation, ataxia and amnesia occur. Conversely,
when GABA is reduced arousal, anxiety and restlessness
occur.
29. Pharmacokinetics
• Most benzodiazepines are well absorbed and rapidly penetrate the brain, producing an effect
within half an hour after oral administration.
• The drugs undergo hepatic metabolism via oxidation or conjugation and some form
pharmacologically active metabolites with even longer elimination half-lives. Oxidation of
benzodiazepines is decreased in the elderly, in patients with hepatic impairment and in the
presence of some drugs, including alcohol.
• Benzodiazepines are metabolized through the cytochrome P450 3A4/3 enzyme system in the liver,
so significant enzyme inducers (such as carbamazepine) may reduce levels while enzyme
inhibitors (e.g. erythromycin) may increase levels.
• Lorazepam and oxazepam are less lipophilic, have a slower onset, but a longer duration of action.
They are not recommended for immediate relief of anxiety.
Picture obtained from “Essentials of Medical pharmacology” by KD Tripathi, 7th edition.
30. Adverse effects:
1. Psychomotor and cognitive impairment.
• Although over sedation is not usually a problem in anxious patients,
there is evidence that long-term use of benzodiazepines results in
psychomotor impairment and has adverse effects on memory.
• Many patients on long-term benzodiazepines complain of poor
memory. In elderly patients, the amnesic effects may falsely suggest
the development of dementia.
2. Paradoxical effects
• Occasionally, benzodiazepines produce paradoxical stimulant effects.
These effects are most marked in anxious subjects and include
excitement, increased anxiety, irritability and outbursts of rage.
31. 3. Affective reactions
• Chronic use of benzodiazepines can aggravate depression, may sometimes
provoke suicide attempts in impulsive patients, and can cause depression
in patients with no previous history of depressive disorder. Aggravation of
depression is a particular risk in anxious patients who often have mixed
anxiety/depression. Benzodiazepines are taken alone or in combination
with other drugs in 40% of self-poisoning incidents.
4. Dependence
• The greatest drawback of chronic benzodiazepine use is the development
of drug dependence. It is generally agreed that the regular use of
therapeutic doses of benzodiazepines as hypnotics or anxiolytics for more
than a few weeks (2–4 weeks) can give rise to dependence, with
withdrawal symptoms on cessation of drug use in over 40% of patients.
32. B. Anti-depressants
Antidepressants can provide a long-term treatment option for those with an anxiety disorder. They are generally recommended
for those who are unable to commit to or have not responded to psychological therapies.
I. Reversible inhibitors of MAO-A (RIMAs)
Moclobemide, Clorgyline
II. Tricyclic antidepressants (TCAs)
A. NA + 5-HT reuptake inhibitors
Imipramine, Amitriptyline, Trimipramine, Doxepin, Dothiepin, Clomipramine
B. Predominantly NA reuptake inhibitors
Desipramine, Nortriptyline, Amoxapine, Reboxetine
III. Selective serotonin reuptake inhibitors (SSRIs)
Fluoxetine, Fluvoxamine, Paroxetine, Sertraline, Citalopram, Escitalopram, Dapoxetine
IV. Serotonin and noradrenaline reuptake inhibitors (SNRIs)
Venlafaxine, Duloxetine
V. Atypical antidepressants
Mirtazapine, Bupropion
33. I. Reversible inhibitors of MAO-A (RIMAs)
• MAO is a mitochondrial enzyme involved in the oxidative deamination of biogenic
amines (Adr, NA, DA, 5-HT). Two isoenzyme forms of MAO have been identified.
• MAO-A: Preferentially deaminates 5-HT and NA, and is inhibited by clorgyline,
moclobemide.
• MAO-B: Preferentially deaminates phenylethylamine and is inhibited by
selegiline.
• Moclobemide : It is a reversible and selective MAO-A inhibitor with short
duration of action; full MAO activity is restored within 1–2 days of stopping the
drug. Because of competitive enzyme inhibition, tyramine is able to displace it
from the enzyme, so that potentiation of pressor response to ingested amines is
minor, and dietary restrictions are not required.
• Adverse effects are nausea, dizziness, headache, insomnia, rarely excitement and
liver damage.
• Dose: 150mg BD or TDS
34. II. Tricyclic antidepressants (TCAs)
MOA: The TCAs and related drugs inhibit NET and SERT which mediate active
reuptake of biogenic amines NA and 5-HT into their respective neurons and
thus potentiate them. Reuptake inhibition results in increased concentration
of the amines in the synaptic cleft in both CNS and periphery.
Pharmacokinetics: The oral absorption of TCAs is good, though often slow.
They are highly bound to plasma and tissue proteins, therefore have large
volumes of distribution (~20 L/kg). They are extensively metabolized in liver;
the major route for imipramine and amitriptyline is demethylation whereby
active metabolites—desipramine and nortriptyline respectively are formed.
Both these metabolites predominantly block NA reuptake. The plasma t½ of
amitriptyline, imipramine and doxepin range between 16–24 hours. The t½ is
longer for some of their active metabolites. Because of relatively long t½s,
once daily dosing (at bed time) is practicable in the maintenance phase.
35. • Adverse effects: Side effects are common with TCAs because of which SSRIs, SNRIs and atypical antidepressants are more preferred these days.
1. Anticholinergic: dry mouth, bad taste, constipation, epigastric distress, urinary retention (especially in males with enlarged prostate), blurred vision,
palpitation.
2. Sedation, mental confusion and weakness, especially with amitriptyline and more sedative congeners.
3. Increased appetite and weight gain is noted with most TCAs.
4. Some patients receiving any antidepressant may abruptly ‘switch over’ to a dysphoric agitated state or to mania.
5. Sweating (despite antimuscarinic action) and fine tremors are relatively common.
6. Seizure threshold is lowered—fits may be precipitated, especially in children.
7. Postural hypotension, especially in older patients.
8. Sexual distress: especially delay or interference with erection and ejaculation.
9. Cardiac arrhythmias, especially in patients with ischaemic heart disease.
10. Rashes and jaundice due to hypersensitivity are rare.
36. Drug Interactions:
1. TCAs potentiate directly acting sympathomimetic amines (present in cold/asthma remedies). Adrenaline containing local anaesthetic
should be avoided. However, TCAs attenuate the action of indirect sympathomimetics (ephedrine, tyramine).
2. TCAs abolish the antihypertensive action of guanethidine and clonidine by preventing their transport into adrenergic neurones.
3. TCAs potentiate CNS depressants, including alcohol and antihistaminics.
4. Phenytoin, phenylbutazone, aspirin and CPZ can displace TCAs from protein binding sites and cause transient overdose symptoms.
5. Phenobarbitone competitively inhibits as well as induces imipramine metabolism. Carbamazepine and other enzyme inducers enhance
metabolism of TCAs.
6. SSRIs inhibit metabolism of several drugs including TCAs—dangerous toxicity can occur if the two are given concurrently.
7. By their anticholinergic property, TCAs delay gastric emptying and retard their own as well as other drug’s absorption. However, digoxin
and tetracyclines may be more completely absorbed. When used together, the anticholinergic action of neuroleptics and TCAs may add
up.
8. MAO inhibitors—dangerous hypertensive crisis with excitement and hallucinations has occurred when given with TCAs.
37. III. Selective serotonin reuptake inhibitors (SSRIs)
• The relative safety and better acceptability of SSRIs has made them 1st line
drugs in depression and allowed their extensive use in anxiety, phobias,
OCD and related disorders.
• The SSRIs produce little or no sedation, do not interfere with cognitive and
psychomotor function or produce anticholinergic side effects.
• They are devoid of α adrenergic blocking action—postural hypotension
does not occur, making them suitable for elderly patients.
• They have practically no seizure precipitating propensity and do not inhibit
cardiac conduction—overdose arrhythmias are not a problem.
• Prominent side effects are gastrointestinal; all SSRIs frequently produce
nausea (due to 5-HT3 receptor stimulation), but tolerance develops over
time.
• Loose motions are due to 5-HT uptake blockade in the gut and activation of
5-HT receptors on enteric plexus neurons. Weight gain is not a problem
with SSRIs, but they more commonly interfere with ejaculation.
38. • They should be used cautiously in children and teenagers, because
about 1 out of 50 children report suicidal ideation as a result of SSRI
treatment.
• The SSRIs inhibit drug metabolizing isoenzymes CYP2D6 and CYP3A4:
elevate plasma levels of TCAs, haloperidol, clozapine, terfenadine,
astemizole, warfarin, β blockers, some BZDs and carbamazepine.
• ‘Serotonin syndrome’ manifesting as agitation, restlessness, rigidity,
hyperthermia, delirium, sweating, twitchings followed by convulsions
can be precipitated when any serotonergic drug (e.g. MAOIs,
tramadol, pethidine) is taken by a patient receiving SSRIs.
39. IV. Serotonin and noradrenaline reuptake inhibitors (SNRIs)
• These agents, may be effective in treating depression in
patients in whom SSRIs are ineffective.
• Furthermore, depression is often accompanied by chronic
painful symptoms, such as backache and muscle aches,
against which SSRIs are also relatively ineffective. This pain is,
in part, modulated by serotonin and norepinephrine
pathways in the CNS.
• Venlafaxine is a potent inhibitor of serotonin reuptake and,
at medium to higher doses, is an inhibitor of norepinephrine
reuptake. It is also a mild inhibitor of dopamine reuptake at
high doses. Doesn’t decrease BP, rather increases the BP.
• Duloxetine is used in panic attack.
• Half life of both antidepressants is around 12 hours. The
metabolites of duloxetine are excreted through kidney, and
should not be used in ERD.
• They don’t decrease BP, rather increase the BP slightly.
• The most common side effects are nausea, head ache, sexual
dysfunction, dizziness, insomnia, sedation, and constipation.
Picture : Lipincott’s
“Pharmacology”, 5th edition.
40. V. Atypical Antidepressants
• The atypical antidepressants are a mixed group of
agents that have actions at several different sites.
They are not any more efficacious than the TCAs or
SSRIs, but their side effect profiles are different.
• Mirtazapine acts by a novel mechanism, viz. blocks α2
auto- (on NA neurons) and hetero- (on 5-HT neurons)
receptors enhancing both NA and 5-HT release.
• It is a sedative because of its potent antihistaminic
activity, but it does not cause the antimuscarinic side
effects of the TCAs, or interfere with sexual
functioning, as do the SSRIs. Increased appetite and
weight gain frequently occur. It is markedly sedating,
which may be an advantage in depressed patients
having difficulty sleeping.
41. • Bupropion: This inhibitor of DA and NA uptake has excitant rather than
sedative property. It is metabolized into an amphetamine like compound
which can cause presynaptic release of DA and NA. Its short half-life may
require more than once-a-day dosing or the administration of an extended-
release formulation. Side effects may include dry mouth, sweating,
nervousness, tremor, a very low incidence of sexual dysfunction, and an
increased risk for seizures at high doses.
• Nefazodone and trazodone: These drugs are weak inhibitors of serotonin
reuptake. Their therapeutic benefit appears to be related to their ability to
block postsynaptic 5-HT2A receptors. With chronic use, these agents may
desensitize 5-HT1A presynaptic autoreceptors and, thereby, increase
serotonin release. Both agents are sedating, probably because of their
potent H1-blocking activity. Trazodone has been associated with causing
priapism, and nefazodone has been associated with the risk for
hepatotoxicity. Both agents also have mild to moderate α1-receptor
antagonism contributing to orthostasis and dizziness.
42. C. β Blockers
• Many symptoms of anxiety (palpitation, rise in BP, shaking, tremor,
gastrointestinal hurrying, etc.) are due to sympathetic overactivity,
and these symptoms reinforce anxiety. Propranolol and other
nonselective β blockers help anxious patients troubled by these
symptoms, by cutting the vicious cycle and provide symptomatic
relief.
• They do not affect the psychological symptoms such as worry, tension
and fear, but are valuable in acutely stressful situations (examination
fear, unaccustomed public appearance, etc.). They may be used for
performance/situational anxiety or as adjuvant to BZDs. The role of β
blockers in anxiety disorders is quite limited.
43. D. Other medications occasionally used in anxiety
• Hydroxyzine, a sedating antihistamine, is licensed for the short term
treatment of anxiety in adults at a dose of 50–100 mg four times a day. The
clinical evidence only supports its use in GAD (for up to 4 weeks) if sedation
is required. NICE supports the use of a sedating antihistamine in the
immediate management of GAD but state they should not be used in panic
disorders (NICE, 2007).
• Usual adult dose: Oral 50-100mg four times a day.
• IM: 50 to 100mg immediately, then every 4-6 hours as needed.
• Pregabalin is licensed for GAD and has shown an anxiolytic effect over
placebo after 1 week in adults or 2 weeks in the elderly (Montgomery et
al., 2008). Two short-term studies (4 and 6 weeks) suggest that pregabalin
400–600 mg/day is as effective but better tolerated than venlafaxine 75
mg/day XL or lorazepam 6 mg/day. Pregabalin, however, commonly causes
dizziness, somnolence and nausea and is more expensive than other
medication options in GAD and should be limited to specialist use only
after other treatments have failed.
44. Management
1. Generalized anxiety disorder
• Goals of Treatment: The goals are to reduce severity, duration, and
frequency of symptoms and improve functioning. The long-term goal
is minimal or no anxiety symptoms, no functional impairment,
prevention of recurrence, and improved quality of life.
• Nonpharmacologic modalities include psychotherapy, short-term
counseling, stress management, cognitive therapy, meditation,
supportive therapy, and exercise. Ideally, patients with GAD should
have psychological therapy, alone or in combination with antianxiety
drugs. Cognitive behavioral therapy (CBT), though not widely available,
is the most effective psychological therapy. Patients should avoid
caffeine, stimulants, excessive alcohol, and diet pills.
45. * Pictures obtained from “Pharmacotherapy, a pathophysiologic approach” by Dipiro, 9th edition.
47. 2. Panic disorder
• Goals of Treatment: The goals are complete resolution of panic
attacks, marked reduction in anticipatory anxiety, elimination of phobic
avoidance, and resumption of normal activities.
General Approach
• SSRIs are first-line agents for panic disorder. Most patients without
agoraphobia improve with pharmacotherapy alone, but if
agoraphobia is present, CBT typically is initiated concurrently. Patients
treated with CBT are less likely to relapse than those treated with
imipramine alone. For patients who cannot or will not take
medications, CBT alone is indicated.
• Educate patient to avoid caffeine, nicotine, alcohol, drugs of abuse,
and stimulants.
48. Starting dose of clonazepam = 0.25 mg twice daily, with a dose increase to 1 mg by the third day. Increases by 0.25 to 0.5 mg every 3 days to 4 mg/day
can be made
if needed.
Starting dose of alprazolam = 0.25 to 0.5 mg three times daily (or 0.5 mg once daily of extended-release alprazolam), slowly increasing over several
weeks as needed. Most patients require 3 to 6 mg/day.
* Pictures obtained from “Pharmacotherapy, a pathophysiologic approach” by Dipiro, 9th edition.
49. 3. Social anxiety disorder
• Goals of Treatment: The goals are to reduce the physiologic symptoms and
phobic avoidance, increase participation in desired social activities, and
improve quality of life.
• Patients with SAD often respond more slowly and less completely than
patients with other anxiety disorders. After improvement, at least 1 year of
maintenance treatment is recommended. Long term treatment may be
needed for patients with unresolved symptoms, comorbidity, an early
onset of disease, or a prior history of relapse.
• CBT (exposure therapy, cognitive restructuring, relaxation training, and
social skills training) and pharmacotherapy are considered equally effective
in SAD, but CBT can lead to a greater likelihood of maintaining response
after treatment termination. Even after response, most patients continue
to experience more than minimal residual symptoms. CBT and social skills
training are effective in children with SAD.
• SSRIs and serotonin norepinephrine reuptake inhibitors are effective in
children 6 to 17 years of age. Individuals up to 24 years of age should be
closely monitored for increased risk of suicide.
50. * Pictures obtained from “Pharmacotherapy, a pathophysiologic approach” by Dipiro, 9th edition.
51. *Paroxetine, sertraline, extended-release fluvoxamine, and extended-release venlafaxine
are first-line agents
* Pictures obtained from “Pharmacotherapy, a pathophysiologic approach” by Dipiro, 9th edition.
52. 4. Post traumatic stress disorder
• Goals of Treatment: The goals are to decrease core symptoms,
disability, and comorbidity and improve quality of life.
• Immediately after the trauma, patients should receive treatment
individualized to their presenting symptoms (eg, nonbenzodiazepine
hypnotic or short courses of CBT). Brief courses of CBT in close
proximity to the trauma can help prevent PTSD.
• If symptoms persist for 3 to 4 weeks, and there is social or
occupational impairment, patients should receive pharmacotherapy
or psychotherapy, or both.
• Psychotherapies for PTSD include stress management, eye movement
desensitization and reprocessing (EMDP), and psychoeducation.
Trauma-focused CBT (TFCBT) and EMDP are more effective than stress
management or group therapy to reduce PTSD symptoms.
53. • Prazosin, in daily doses of 1 to 4 mg, can be useful in some patients with PTSD.
• See patients frequently for the first 3 months, then monthly for 3 months. In months 6 to 12, patients can be
seen every 2 months. Monitor for symptom response, suicidal ideation, disability, side effects, and treatment
adherence.
* Pictures obtained from “Pharmacotherapy, a pathophysiologic approach” by Dipiro, 9th edition.
54. References:
• KD Tripathi (2013) Essentials of Medical Pharmacology, 7th edn., :
Jaypee Brothers Medical Publishers Private Limited.
• Michelle A. Clark, Richard Finkel, Jose A. Rey, Karen Whalen
(2012) Pharmacology, 5th edn., : Lipincott's Illustrated Reviews.
• Barbara G. Wells, Joseph T. DiPiro, Terry L. Schwinghammer and Cecily
V. DiPiro (2012) Pharmacotherapy Handbook, 9th edn., : Mc Graw Hill
Education.
• Roger Walker and Cate Whittlesea (2012) Clinical Pharmacy and
Therapeutics, 5th edn., London, UK: ChurchHill Livingstone.
• http://www.guiasalud.es/egpc/traduccion/ingles/ansiedad/completa/
apartado08/estrategias.html